Skip to main content

Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition

The four winning lesson plans are now available on sharemylesson.comLesson plans showcase creative ways to build awareness of rare disease and to build diversity and inclusion in the classroomCAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the four winners of the Rare Lessons lesson planning competition. Sarepta has granted the winning authors $2,500 each and $2,500 to the educational institution with which each is affiliated. The winning submissions are now available on sharemylesson.com, and more information about the authors can be found at Sarepta.com/rarelessons.Rare Lessons competition winners and lesson plan titles:Laura Doyle, Atlanta International School, Atlanta, Ga.: Rare Diseases Lesson PlanJessica Keogh, West Chester Area School District, Exton, Penn.: EmpathySarah Kesty, Castle Park Middle School, Chula Vista, Calif.: The Mystery of Rare DiseasesKaitlin Payne, South Topsail Elementary School, Hampstead, N.C.: Not Weird, Just Different“Each of these lesson plans is unique, but share in their creativity, passion and innovative thinking aimed at building awareness of rare disease and promoting diversity and inclusion within the classroom and community. Though judges were blinded to author identity and background, another remarkable commonality is the recipients’ connections to rare disease, in most cases either living with a rare disease or caring for a loved one with a rare disease,” said Diane Berry, Ph.D., Sarepta’s Senior Vice President of Global Health Policy, Government and Patient Affairs. “We encourage everyone to share the sharemylesson.com links with educators in your lives, take action to start a conversation and increase understanding of rare disease, and ultimately help alleviate feelings of isolation often experienced by children and families having to navigate living with a rare disease. Sarepta congratulates all the winning authors and extends our thanks and appreciation to all contest entrants and the selection committee for generously giving of their time to review the lesson plan submissions.”This program is intended to promote the development and implementation of educational materials to increase rare disease awareness in the K-12 classroom setting. The competition was open to educators in grades K-12, based in the United States, and actively teaching in an accredited educational institution. A blinded selection committee reviewed and selected the submissions. For the Rare Lessons contest, Sarepta partnered with sharemylesson.com, a platform that offers broad availability of lesson plans for educators and schools across the country.About Sarepta Therapeutics
At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit www.sarepta.com or follow us on TwitterLinkedInInstagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.Sarepta Therapeutics, Inc.Investors:
Ian Estepan, 617-274-4052, iestepan@sarepta.com
Media:
Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.